DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Bridgefront Capital LLC

Bridgefront Capital LLC decreased its position in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 73.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,759 shares of the medical device company's stock after selling 10,437 shares during the period. Bridgefront Capital LLC's holdings in DexCom were worth $292,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Captrust Financial Advisors lifted its holdings in shares of DexCom by 22.1% during the fourth quarter. Captrust Financial Advisors now owns 28,152 shares of the medical device company's stock worth $2,189,000 after purchasing an additional 5,101 shares during the period. Caxton Associates LP acquired a new stake in DexCom during the 4th quarter valued at approximately $23,331,000. Avidity Partners Management LP boosted its holdings in shares of DexCom by 32.5% in the 4th quarter. Avidity Partners Management LP now owns 318,000 shares of the medical device company's stock valued at $24,731,000 after acquiring an additional 78,000 shares during the last quarter. Banque Transatlantique SA purchased a new stake in shares of DexCom in the 4th quarter valued at $119,000. Finally, Bellevue Group AG increased its stake in shares of DexCom by 2.8% in the fourth quarter. Bellevue Group AG now owns 1,045,044 shares of the medical device company's stock worth $81,273,000 after acquiring an additional 28,006 shares during the period. Institutional investors and hedge funds own 97.75% of the company's stock.

Insider Buying and Selling

In other DexCom news, CEO Kevin R. Sayer sold 32,498 shares of the company's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $2,287,209.24. Following the transaction, the chief executive officer now owns 372,029 shares of the company's stock, valued at $26,183,401.02. This represents a 8.03 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, COO Jacob Steven Leach sold 14,076 shares of DexCom stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $990,668.88. Following the sale, the chief operating officer now owns 313,497 shares of the company's stock, valued at approximately $22,063,918.86. This represents a 4.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 66,926 shares of company stock worth $4,734,384. Company insiders own 0.32% of the company's stock.

DexCom Trading Down 0.8 %

DexCom stock traded down $0.68 during trading on Friday, reaching $84.66. 3,348,982 shares of the company were exchanged, compared to its average volume of 4,331,690. The stock's 50 day simple moving average is $71.08 and its two-hundred day simple moving average is $77.17. The company has a market capitalization of $33.20 billion, a P/E ratio of 59.20, a PEG ratio of 2.30 and a beta of 1.43. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. DexCom, Inc. has a 52-week low of $57.52 and a 52-week high of $132.26.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). The firm had revenue of $1.04 billion during the quarter, compared to analysts' expectations of $1.02 billion. DexCom had a net margin of 14.29% and a return on equity of 30.14%. The company's revenue for the quarter was up 12.5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.32 EPS. On average, equities research analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

DXCM has been the subject of a number of research reports. Redburn Atlantic upgraded shares of DexCom from a "neutral" rating to a "buy" rating and boosted their target price for the company from $85.00 to $115.00 in a research report on Monday, February 3rd. Robert W. Baird lowered their target price on DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a research note on Friday, May 2nd. Mizuho initiated coverage on shares of DexCom in a research note on Thursday, April 10th. They set an "outperform" rating and a $85.00 price objective on the stock. Canaccord Genuity Group boosted their target price on shares of DexCom from $103.00 to $106.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Finally, Morgan Stanley raised their price target on shares of DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a research report on Friday, February 14th. Five equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, DexCom has a consensus rating of "Moderate Buy" and an average price target of $98.11.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.